Dual Anti-CD19/Anti-CD20 CAR T-Cells (NCI)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDual Anti-CD19/Anti-CD20 CAR T-Cells (NCI)
Drug Alias NameCD19/CD20 CAR-T cellsBispecific Anti-CD19/Anti-CD20 CAR T-Cell Therapy (National Cancer Institute)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A